EyeGate Pharmaceuticals, Inc. Aktie News

On the heels of crossing the $1 billion threshold in active ETF AUM, AllianceBernstein has launched five active exchange-traded funds today: two on the New York Stock Exchange, and three on the Nasdaq.

Lineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn. , Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P.

The stock price of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) increased 22.95% in the previous trading session. This is why it happened.

Investing in penny stocks in 2021? Check these three out for next months watchlist The post Best Penny Stocks to Buy Right Now?

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in on...

-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-

WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent...

WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced the closing of its previously announced registered direct offering priced at-the-marked un...